Literature DB >> 20029444

Interaction between capecitabine and brivudin in a patient with breast cancer.

José M Baena-Cañada1, María J Martínez, Obdulia García-Olmedo, Reyes Jiménez-Bárcenas, Pedro Muriel-Cueto.   

Abstract

BACKGROUND: A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin. A drug-drug interaction between brivudin and capecitabine caused medullar aplasia, serious toxic effects to the intestinal mucous membrane, hand-foot syndrome, onycholysis and dental pigmentation. INVESTIGATIONS: Physical examination, blood analysis, blood cultures, chest X-ray, bone marrow aspiration and biopsy. DIAGNOSIS: Serious adverse event secondary to inhibition of dihydropyrimidine dehydrogenase by a drug-drug interaction between capecitabine and brivudin. MANAGEMENT: Intravenous hydration, imipenem, red blood cell and platelet transfusions, filgrastim, omeprazole, care of the mouth and feet, topical anesthetics, systemic analgesics and parenteral nutrition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20029444     DOI: 10.1038/nrclinonc.2009.185

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  15 in total

1.  Fatal drug-drug interaction of brivudine and capecitabine.

Authors:  Alexandra E Rätz Bravo; Silvia Hofer; Stephan Krähenbühl; Christian Ludwig
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

2.  Nomenclature for human DPYD alleles.

Authors:  H L McLeod; E S Collie-Duguid; P Vreken; M R Johnson; X Wei; A Sapone; R B Diasio; P Fernandez-Salguero; A B van Kuilenberg; A H van Gennip; F J Gonzalez
Journal:  Pharmacogenetics       Date:  1998-12

3.  Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.

Authors:  T Nishiyama; K Ogura; H Okuda; K Suda; A Kato; T Watabe
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

4.  National surveillance of emergency department visits for outpatient adverse drug events.

Authors:  Daniel S Budnitz; Daniel A Pollock; Kelly N Weidenbach; Aaron B Mendelsohn; Thomas J Schroeder; Joseph L Annest
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

5.  Drug-induced illness leading to hospitalization.

Authors:  G J Caranasos; R B Stewart; L E Cluff
Journal:  JAMA       Date:  1974-05-06       Impact factor: 56.272

6.  Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.

Authors:  H Nakayama; T Kinouchi; K Kataoka; S Akimoto; Y Matsuda; Y Ohnishi
Journal:  Pharmacogenetics       Date:  1997-02

7.  [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

Authors:  E A Hooiveld; A B van Kuilenburg; J B Haanen; A M Westermann
Journal:  Ned Tijdschr Geneeskd       Date:  2004-03-27

8.  Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study.

Authors:  Sawko W Wassilew; Peter Wutzler
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

Review 9.  Onycholysis associated with capecitabine in patients with breast cancer.

Authors:  Marcia Hogeling; Jessica Howard; Nordau Kanigsberg; Harvey Finkelstein
Journal:  J Cutan Med Surg       Date:  2008 Mar-Apr       Impact factor: 2.092

10.  Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.

Authors:  R B Diasio
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

View more
  5 in total

1.  Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review.

Authors:  Manvi Sharma; Aisha Vadhariya; Soumya Chikermane; Suma Gopinathan; Mariana Chavez-MacGregor; Sharon H Giordano; Michael L Johnson; Holly M Holmes
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

2.  Implementation of safeguards to improve patient safety in chemotherapy.

Authors:  M J Huertas-Fernández; Mª J Martínez-Bautista; M E Rodríguez-Mateos; M Zarzuela-Ramírez; T Muñoz-Lucero; J M Baena-Cañada
Journal:  Clin Transl Oncol       Date:  2017-03-30       Impact factor: 3.405

Review 3.  Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.

Authors:  Huai-Liang Wu; Yue Gong; Peng Ji; Yi-Fan Xie; Yi-Zhou Jiang; Guang-Yu Liu
Journal:  J Hematol Oncol       Date:  2022-04-27       Impact factor: 23.168

Review 4.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

Review 5.  Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.

Authors:  Shafina Siddiqui; Ankita Jaywant Deshmukh; Priyanka Mudaliar; Apoorva Jagannath Nalawade; Deepak Iyer; Jyotirmoi Aich
Journal:  J Egypt Natl Canc Inst       Date:  2022-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.